SCHEMBL8488385

SCHEMBL8488385

CC(CCO)C(=O)N1CCOCC1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.55
CYP2C19 P33261 1/20 0.55
GAA P10253 2/20 0.54
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.44
PKM P14618 1/20 0.44
TSHR P16473 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A1 P00352 4/20 0.43
KMT2A Q03164 1/20 0.42
POLB P06746 1/20 0.41
MAPT P10636 2/20 0.41
FKBP1A P62942 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA9 Q16790 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8488383 0.85 CYP3A4 (0.55) CYP3A4CYP2C19GAAHTTSMN1; SMN2
SCHEMBL20733007 0.85 CYP3A4 (0.59) CYP3A4CYP2C19GAAHTTSMN1; SMN2
SCHEMBL8488180 0.85 CYP3A4 (0.58) CYP3A4CYP2C19GAAHTTSMN1; SMN2
SCHEMBL8487717 0.82 DPP7 (0.40) CYP3A4CYP2C19HTTALDH1A1HPGD
SCHEMBL19792871 0.82 CYP3A4 (0.56) CYP3A4CYP2C19GAAHTTSMN1; SMN2
SCHEMBL9028053 0.82 CYP3A4 (0.53) CYP3A4CYP2C19GAAHTTSMN1; SMN2
SCHEMBL8488177 0.81 CYP3A4 (0.58) CYP3A4CYP2C19GAAHTTSMN1; SMN2
SCHEMBL4700991 0.81 CYP3A4 (0.63) CYP3A4CYP2C19GAAHTTSMN1; SMN2
SCHEMBL13259745 0.81 CYP3A4 (0.63) CYP3A4CYP2C19GAAHTTSMN1; SMN2
SCHEMBL8489452 0.81 DPP7 (0.42) CYP3A4CYP2C19HTTL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120172321-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-05 US disclosed
US-8071766-B2 HSP90 inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-12-06 US disclosed
US-20110053873-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-03-03 US disclosed
US-20090305998-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-10 US disclosed
US-5958837-A 2-(PHENYLMETHOXY OR CARBONYLOXY-(1,4-PHENYLENE)-),3-HALO,5-HALOALKYLPYRIDINES; HERBICIDES EFFECTING DESICCATION AND DEFOLIATION OF PLANTS; GOOD ACTIVITY AND BETTER TAILORED CONTROL OF WEEDS BASF AKTIENGESELLSCHAFT (DE) 1999-09-28 US disclosed
EP-0802904-B1 SUBSTITUTED 2-PHENYLPYRIDINES AS HERBICIDES BASF AG (DE) 1998-09-09 EP disclosed
EP-0802904-A1 SUBSTITUTED 2-PHENYLPYRIDINES AS HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1997-10-29 EP disclosed
WO-1996021647-A1 SUBSTITUTED 2-PHENYLPYRIDINES AS HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1996-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090305998-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 CYP3A4 3279/4885CYP2C19 1824/4885GAA 221/4885
US-20110053873-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 CYP3A4 3427/4885CYP2C19 2066/4885GAA 284/4885
US-20120172321-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 CYP3A4 3279/4885CYP2C19 1824/4885GAA 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.